RU2208608C2 - Амиды кислот, способ их получения и фармацевтическая композиция на их основе - Google Patents

Амиды кислот, способ их получения и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2208608C2
RU2208608C2 RU2001122727/04A RU2001122727A RU2208608C2 RU 2208608 C2 RU2208608 C2 RU 2208608C2 RU 2001122727/04 A RU2001122727/04 A RU 2001122727/04A RU 2001122727 A RU2001122727 A RU 2001122727A RU 2208608 C2 RU2208608 C2 RU 2208608C2
Authority
RU
Russia
Prior art keywords
compound
substituted
salt
reaction
dichloromethane
Prior art date
Application number
RU2001122727/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001122727A (ru
Inventor
Акира ЯМАДА (JP)
Акира Ямада
Сатоси АОКИ (JP)
Сатоси АОКИ
Original Assignee
Фудзисава Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко., Лтд. filed Critical Фудзисава Фармасьютикал Ко., Лтд.
Publication of RU2001122727A publication Critical patent/RU2001122727A/ru
Application granted granted Critical
Publication of RU2208608C2 publication Critical patent/RU2208608C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2001122727/04A 1999-01-14 2000-01-06 Амиды кислот, способ их получения и фармацевтическая композиция на их основе RU2208608C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
AUPP8180 1999-01-14

Publications (2)

Publication Number Publication Date
RU2001122727A RU2001122727A (ru) 2003-05-20
RU2208608C2 true RU2208608C2 (ru) 2003-07-20

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001122727/04A RU2208608C2 (ru) 1999-01-14 2000-01-06 Амиды кислот, способ их получения и фармацевтическая композиция на их основе

Country Status (21)

Country Link
US (2) US6710043B1 (https=)
EP (1) EP1140836B1 (https=)
JP (2) JP3617454B2 (https=)
KR (2) KR100525809B1 (https=)
CN (1) CN1142910C (https=)
AR (1) AR028812A1 (https=)
AT (1) ATE502923T1 (https=)
AU (1) AUPP818099A0 (https=)
BR (1) BRPI0008753B8 (https=)
CA (1) CA2360360C (https=)
CZ (1) CZ20012562A3 (https=)
DE (1) DE60045759D1 (https=)
ES (1) ES2363492T3 (https=)
HK (1) HK1044337B (https=)
HU (1) HU230422B1 (https=)
IL (2) IL143841A0 (https=)
RU (1) RU2208608C2 (https=)
TR (1) TR200102038T2 (https=)
TW (1) TWI229075B (https=)
WO (1) WO2000042011A1 (https=)
ZA (1) ZA200104713B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8188289B2 (en) 2006-03-13 2012-05-29 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CA2431181A1 (en) * 2000-12-07 2002-06-13 Nobuya Matsuoka Nootropic effect enhancer
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2004052102A1 (en) * 2002-12-06 2004-06-24 Dow Agrosciences Llc Synergistic compositions
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
CA2579227A1 (en) * 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
WO2007031791A1 (en) 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20080200444A1 (en) * 2006-10-20 2008-08-21 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
CN101687795B (zh) 2007-04-20 2013-05-08 千寿制药株式会社 轴突形成促进剂
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229493A2 (en) * 1985-12-14 1987-07-22 Minnesota Mining And Manufacturing Company Device for dispensing flowable material from a bag
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts
EP0625507A2 (en) * 1993-05-21 1994-11-23 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as acat inhibitors
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (https=) * 1969-06-30 1974-10-28
US3647805A (en) 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (https=) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
DE2860314D1 (en) * 1977-11-24 1981-02-19 Synthelabo Derivatives of naphthalene, process for their preparation and their therapeutic application
DE3784401T2 (de) 1986-07-31 1993-08-12 Otsuka Pharma Co Ltd Karbostyril-derivate und ihre salze, verfahren zu ihrer herstellung und diese enthaltende kardiotonische zusammensetzung.
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
ATE219766T1 (de) 1993-04-07 2002-07-15 Otsuka Pharma Co Ltd N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
PT704439E (pt) * 1993-06-18 2001-12-28 Fujisawa Pharmaceutical Co Novo intermediario para utilizacao sintetica e processo para a preparacao de derivados de aminopiperazina
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
MX9707561A (es) 1995-04-07 1997-12-31 Schering Corp Compuestos de carbonil piperazinilo y piperidinilo.
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
JP2001506580A (ja) * 1996-12-24 2001-05-22 藤沢薬品工業株式会社 アミノピペラジン誘導体の新規用途
EP0968201A2 (en) 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229493A2 (en) * 1985-12-14 1987-07-22 Minnesota Mining And Manufacturing Company Device for dispensing flowable material from a bag
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
EP0625507A2 (en) * 1993-05-21 1994-11-23 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as acat inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8188289B2 (en) 2006-03-13 2012-05-29 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9029550B2 (en) 2006-03-13 2015-05-12 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase

Also Published As

Publication number Publication date
AR028812A1 (es) 2003-05-28
BRPI0008753B8 (pt) 2021-05-25
JP2004002414A (ja) 2004-01-08
CA2360360C (en) 2009-09-08
IL143841A (en) 2006-07-05
KR100520406B1 (ko) 2005-10-11
HUP0105108A3 (en) 2002-11-28
WO2000042011A1 (en) 2000-07-20
AUPP818099A0 (en) 1999-02-11
JP3617454B2 (ja) 2005-02-02
CN1142910C (zh) 2004-03-24
CA2360360A1 (en) 2000-07-20
US20040014745A1 (en) 2004-01-22
TR200102038T2 (tr) 2002-01-21
ATE502923T1 (de) 2011-04-15
EP1140836B1 (en) 2011-03-23
KR20010093819A (ko) 2001-10-29
KR20040063001A (ko) 2004-07-09
HUP0105108A2 (hu) 2002-05-29
EP1140836A1 (en) 2001-10-10
US6710043B1 (en) 2004-03-23
HK1044337A1 (en) 2002-10-18
HK1044337B (zh) 2004-11-26
DE60045759D1 (de) 2011-05-05
KR100525809B1 (ko) 2005-11-03
ZA200104713B (en) 2002-09-09
TWI229075B (en) 2005-03-11
CN1336917A (zh) 2002-02-20
JP2002534503A (ja) 2002-10-15
CZ20012562A3 (cs) 2001-11-14
HU230422B1 (hu) 2016-05-30
BR0008753B1 (pt) 2013-11-12
ES2363492T3 (es) 2011-08-05
IL143841A0 (en) 2002-04-21
BR0008753A (pt) 2001-11-06

Similar Documents

Publication Publication Date Title
RU2208608C2 (ru) Амиды кислот, способ их получения и фармацевтическая композиция на их основе
US6291464B1 (en) Aminopiperazine derivatives
JP3152440B2 (ja) ニューロキニンアンタゴニストとして有用な置換オキシム誘導体
JP4025200B2 (ja) ピペリジンmchアンタゴニストおよび肥満の処置におけるそれらの使用
JP4592077B2 (ja) 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−1(nk−1)アンタゴニストとしての1−アミド−4−フェニル−4−ベンジルオキシメチル−ピペリジン誘導体および関連化合物
AU598905B2 (en) N-heterocyclic-n-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
US20060122197A1 (en) Amido compounds and their use as pharmaceuticals
PT1492786E (pt) Piridinoilpiperidinas como agonistas do 5-ht1f
TW200815431A (en) Azabenzimidazolyl compounds
JP2005511621A (ja) ケモカインレセプターの調節物質としての新規ピペリジン誘導体
JP2002517480A (ja) インテグリンインヒビターとしてのフェニルアラニン誘導体
JP2003531141A (ja) エナミン誘導体
JP2008540500A (ja) ニューロキニン受容体拮抗物質としてのキノリン誘導体
PT1663971E (pt) 2-carbonilamino-6-piperidinaminopiridinas substituídas e 1-carbonilamino-3-piperidinaminobenzenos substituídos como agonistas de 5-ht1f
ES2226493T3 (es) Oximas e hidrazonas sustituidas como antagonistas de neroquinina.
AU760434B2 (en) Amide compounds
ES2396557T3 (es) Derivado de benciloxipropilamina
JP2003535088A (ja) 2,7−ナフチリジン誘導体
MXPA01006630A (en) Amide compounds
JP2003535081A (ja) 3−置換イソキノリン−1−イル誘導体
MXPA98006690A (es) Antagonistas del receptor ccr-3

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
RH4A Copy of patent granted that was duplicated for the russian federation

Effective date: 20060227